These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 7793213

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Attenuation of serotonin-induced contractures in skeletal muscle from malignant hyperthermia-susceptible patients with dantrolene.
    Wappler F, Scholz J, von Richthofen V, Fiege M, Köchling A, Lambrecht W, Schulte am Esch J.
    Acta Anaesthesiol Scand; 1997 Nov; 41(10):1312-8. PubMed ID: 9422298
    [Abstract] [Full Text] [Related]

  • 4. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
    Hartung E, Koob M, Anetseder M, Schoemig P, Krauspe R, Hogrefe G, Engelhardt W.
    Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
    [Abstract] [Full Text] [Related]

  • 5. [Ryanodine-induced contractures for the diagnosis of malignant hyperthermia susceptibility].
    Lenzen C, Roewer N, Scholz J, Rumberger E, Schulte am Esch J.
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1991 Dec; 26(8):459-63. PubMed ID: 1786306
    [Abstract] [Full Text] [Related]

  • 6. Dantrolene--in vitro studies in malignant hyperthermia susceptible (MHS) and normal skeletal muscle.
    Britt BA, Scott E, Frodis W, Clements MJ, Endrenyi L.
    Can Anaesth Soc J; 1984 Mar; 31(2):130-54. PubMed ID: 6704779
    [Abstract] [Full Text] [Related]

  • 7. Accelerated contractures after administration of ryanodine to skeletal muscle of malignant hyperthermia susceptible patients.
    Lenzen C, Roewer N, Wappler F, Scholz J, Kahl J, Blank M, Rumberger E, Schulte am Esch J.
    Br J Anaesth; 1993 Aug; 71(2):242-6. PubMed ID: 8123400
    [Abstract] [Full Text] [Related]

  • 8. Changes in ryanodine-induced contractures by stimulus frequency in malignant hyperthermia susceptible and malignant hyperthermia nonsusceptible dog skeletal muscle.
    Sudo RT, Nelson TE.
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1331-6. PubMed ID: 9316843
    [Abstract] [Full Text] [Related]

  • 9. Ryanodine contracture threshold times for diagnosis of malignant hyperthermia susceptibility: an experimental approach from a single laboratory.
    Weisshorn R, Wappler F, Fiege M, Gerbershagen MU, Kolodzie K, Alberts P, Horn EP, Schulte Am Esch J.
    J Clin Anesth; 2004 Aug; 16(5):353-7. PubMed ID: 15374556
    [Abstract] [Full Text] [Related]

  • 10. In vitro diagnosis of malignant hyperthermia susceptibility with ryanodine-induced contractures in human skeletal muscles.
    Wappler F, Roewer N, Köchling A, Scholz J, Steinfath M, Schulte am Esch J.
    Anesth Analg; 1996 Jun; 82(6):1230-6. PubMed ID: 8638796
    [Abstract] [Full Text] [Related]

  • 11. 3,5-Di-t-butyl catechol is a potent human ryanodine receptor 1 activator, not suitable for the diagnosis of malignant hyperthermia susceptibility.
    Lacava C, Michalek-Sauberer A, Kraft B, Sgaragli G, Sipos E, Höller C, Kress HG, Fusi F, Weigl LG.
    Pharmacol Res; 2012 Jul; 66(1):80-7. PubMed ID: 22480578
    [Abstract] [Full Text] [Related]

  • 12. Porcine malignant hyperthermia: effect of dantrolene sodium on in-vitro halothane-induced contraction of susceptible muscle.
    Anderson IL, Jones EW.
    Anesthesiology; 1976 Jan; 44(1):57-61. PubMed ID: 1244776
    [Abstract] [Full Text] [Related]

  • 13. Effects of the phosphodiesterase-III inhibitor enoximone on skeletal muscle specimens from malignant hyperthermia susceptible patients.
    Fiege M, Wappler F, Scholz J, Weisshorn R, von Richthofen V, Schulte am Esch J.
    J Clin Anesth; 2000 Mar; 12(2):123-8. PubMed ID: 10818326
    [Abstract] [Full Text] [Related]

  • 14. Effects of the serotonin2 receptor agonist DOI on skeletal muscle specimens from malignant hyperthermia-susceptible patients.
    Wappler F, Roewer N, Köchling A, Scholz J, Löscher W, Steinfath M.
    Anesthesiology; 1996 Jun; 84(6):1280-7. PubMed ID: 8669667
    [Abstract] [Full Text] [Related]

  • 15. [Diagnosis of susceptibility to malignant hyperthermia with an in vitro contracture test with the phosphodiesterase iii inhibitor enoximone].
    Fiege M, Wappler F, Scholz J, von Richthofen V, Brinken B, Schulte am Esch J.
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Sep; 33(9):557-63. PubMed ID: 9787864
    [Abstract] [Full Text] [Related]

  • 16. Effect of diltiazem and dantrolene on the contractility of isolated malignant hyperpyrexia-susceptible porcine skeletal muscle.
    Foster PS, Denborough MA.
    Br J Anaesth; 1989 May; 62(5):566-72. PubMed ID: 2730830
    [Abstract] [Full Text] [Related]

  • 17. [Effects of serotonin 2 receptor agonists on skeletal muscle preparations in patients with a disposition toward malignant hyperthermia].
    Wappler F, Roewer N, Köchling A, Scholz J, Steinfath M, Rumberger E, Löscher W, Schulte am Esch J.
    Anaesthesist; 1995 Aug; 44(8):538-44. PubMed ID: 7573901
    [Abstract] [Full Text] [Related]

  • 18. Effect of diltiazem, verapamil and dantrolene on the contractility of isolated malignant hyperpyrexia-susceptible human skeletal muscle.
    Foster PS, Hopkinson KC, Denborough MA.
    Clin Exp Pharmacol Physiol; 1989 Oct; 16(10):799-805. PubMed ID: 2612062
    [Abstract] [Full Text] [Related]

  • 19. The control of muscle contracture by the action of dantrolene on the sarcolemma.
    Halsall PJ, Ellis FR.
    Acta Anaesthesiol Scand; 1983 Jun; 27(3):229-32. PubMed ID: 6880584
    [Abstract] [Full Text] [Related]

  • 20. High-purity ryanodine and 9,21-dehydroryanodine for in vitro diagnosis of malignant hyperthermia in man.
    Wappler F, Roewer N, Lenzen C, Köchling A, Scholz J, Steinfath M, Schulte am Esch J.
    Br J Anaesth; 1994 Feb; 72(2):240-2. PubMed ID: 8110584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.